An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date

References

• Kullberg BJ, Arendrup MC, Campion EW. Invasive candidiasis. N Engl J Med.. 2015;373(15):1445–1456.
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370(13):1198–1208.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018 May;4(1):18026.
   PubMedGoogle Scholar
• Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis.. 2007;26:271–276.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infect Dis. 2019 Mar;6(Suppl Supplement_1):S79–S94.
   PubMedGoogle Scholar
• Ricotta EE, Lai YL, Babiker A, et al. Invasive candidiasis species distribution and trends, United States, 2009–2017. J Infect Dis. 2020 Aug 15:jiaa502. doi10.1093/infdis/jiaa502.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017 Aug 15;216(suppl_3):S445–S451.
   PubMedGoogle Scholar
• Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis.. 1996 Nov;23(5):964–972.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb;62(4):e1–e50.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Arendrup MC, Chaturvedi VP, et al., Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics. 9(9): 539. 2020.
   Google Scholar
• Gonzalez-Lara MF, Ostrosky-Zeichner L. Invasive candidiasis. Semin Respir Crit Care Med. 2020;41(01):003–012.
   PubMedGoogle Scholar
• Bayona JVM, Palop NT, Garcia CS, et al. Characteristics and management of candidaemia episodes in an established Candida auris outbreak. Antibiotics. 2020;9(9):558.
   Google Scholar
• Wring SA, Randolph R, Park SH, et al., Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 61(4): e02068–16. 2017.
   PubMed Web of Science ®Google Scholar
• Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: a novel oral glucan synthase inhibitor. Medical Mycology. 2020;58(5):579–592.
   PubMed Web of Science ®Google Scholar
• Jimenez-Ortigosa C, Perez WB, Angulo D, et al. De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance. Antimicrob Agents Chemother. 2017;61(9):e00833–17.
   PubMed Web of Science ®Google Scholar
• Rauseo AM, Coler-Reilly A, Larson L, et al. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020 Jan 12;7(2):ofaa016.
   PubMed Web of Science ®Google Scholar
• Scynexis Press Release. Scynexis’ oral SCY-078 receives FDA QIDP and Fast Track Designations for the treatment of VVC and prevention of recurrent VVC. 2018 May 1. Available at: https://www.scynexis.com/news-media/press-releases/detail/147/scynexiss-oral-scy-078-receives-fda-qidp-and-fast-track
   Google Scholar
• Scorneaux B, Angulo D, Borroto-Esoda K, et al. SCY-078 is fungicidal against Candida Sspecies in time-kill studies. Antimicrob Agents Chemother.. 2017;61(3):e01961–16.
   PubMed Web of Science ®Google Scholar
• Berkow EL, Angulo D, Lockhart SR. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00435–17.
   PubMed Web of Science ®Google Scholar
• Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61(5):e02396–16.
   PubMed Web of Science ®Google Scholar
• Azie N, Angulo D, Dehn B, et al. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Expert Opin Investig Drugs. 2020 Sep;29(9):893–900.
   PubMed Web of Science ®Google Scholar
• Jiménez-Ortigosa C, Paderu P, Motyl MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother.. 2014;58(2):1248–1251.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013;57(2):1065–1068.
   PubMed Web of Science ®Google Scholar
• Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015 Jul;59(7):4308–4311.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Long L, Larkin EL, et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. Antimicrob Agents Chemother.. 2018;62(6):e00244–18.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. By two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013;68:850–863.
   Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Differential Activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother.. 2017;61(8):e00161–17.
   PubMed Web of Science ®Google Scholar
• Schell WA, Jones AM, Borroto-Esoda K, et al. Antifungal Activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):e01102–17.
   PubMed Web of Science ®Google Scholar
• Marcos-Zambrano LJ, Gomez-Perosanz MG, Escribano P, et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017 Jul 1;72(7):1969–1976.
   PubMed Web of Science ®Google Scholar
• Pham CD, Iqbal N, Bolden CB, et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother. 2014;58(8):4690–4696.
   PubMed Web of Science ®Google Scholar
• Nunnally NS, Etienne KA, Angulo D, et al. In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against candida glabrata isolates with FKS Mutations. Antimicrob Agents Chemother. 2019 Nov;63(11):e01692–19.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Long L, Isham N, et al. Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata. Antimicrob Agents Chemother. 2019 Dec;63(12):e01510–19.
   Web of Science ®Google Scholar
• Zhu YC, Barat SA, Borroto-Esoda K, et al. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922.
   PubMed Web of Science ®Google Scholar
• Wring S, Borroto-Esoda K, Solon E, et al. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e02119–18.
   PubMed Web of Science ®Google Scholar
• Lee A, Pridequx B, Lee M, et al. Penetration of ibrexafungerp (formerly SCY-078) at the site of infection in an intra-abdominal candidiasis mouse model. Antimicrob Agents Chemother. 2020 Feb;64(3):e02269–19.
   Web of Science ®Google Scholar
• Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265–1272.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Jaramillo R, et al. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. J Antimicrob Chemother.. 2018;73(2):448–451.
   PubMed Web of Science ®Google Scholar
• Trucksis M, Garrett G, Herman I, et al. A phase I single rising dose study evaluating the safety, tolerability and pharmacokinetics of an oral glucan synthase inhibitor in healthy male volunteers. Abstract (no. F1-1975) presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sept 12–15; Boston, Massachusetts, USA.
   Google Scholar
• Trucksis M, Garrett G, Bautmans A, et al. A phase I multiple rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor, in healthy volunteers. Poster (no. F1-1390) presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sept 17–20; Chicago, Illinois, USA.
   Google Scholar
• Wring S, Murphy G, Atiee G, et al. Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions. J Clin Pharmacol. 2018 Oct;58(10):1305–1313.
   PubMed Web of Science ®Google Scholar
• Wring S, Murphy G, Atiee G, et al. Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus. Clin Pharmacol Drug Dev. 2019 Jan;8(1):60–69.
   PubMed Web of Science ®Google Scholar
• Murphy G, Darpo B, Marbury T, et al. Lack of an effect of SCY-078 a novel antifungal agent on QTc interval in healthy subjects. Abstract (no. 172) presented American Society for Microbiology (ASM), 2017 June 1–5. New Orleans, LA, USA.
   Google Scholar
• Spec A, Pullman J, Thompson GR, et al., MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 74(10): 3056–3062. 2019.
   PubMed Web of Science ®Google Scholar
• Azie NA A phase 2b, dose-finding study evaluating oral ibrexafungerp in moderate to severe acute vulvovaginal candidiasis (DOVE). Presented at: 3rd International Society for Infectious Diseases in Obstetrics and Gynecology Congress. 2019 . Portugal.
   Google Scholar
• Scynexis Press Release. Scynexis announces SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection): SCYNEXIS, Inc. (SCYX). 2020 Apr 21. Available at: https://www.scynexis.com/news-media/press-releases/detail/207/scynexis-announces-positive-top-line-results-from-its
   Google Scholar
• Silva LN, deMello TP, de Souza Ramos L, et al. New and promising chemotherapeutics for emerging infections involving drug-resistant non-albicans Candida species. Curr Top Med Chem. 2019;19:2527–2553.
   PubMed Web of Science ®Google Scholar
• Juneja D, Singh O, Tarai B, et al. Successful treatment of two patients with Candida auris candidemia with the investigational agent, oral ibrexafungerp (formerly SCY-078) from the CARES Study; Poster (no. L0028) presented at: 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID): 2019 April 13–16. Amsterdam, Netherlands.
   Google Scholar
• Alexander B, Kohler P, Pappas P et al. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). In ECCMID 2020 Abstract Book. Abstract #9710, page 4490. Available at: https://www.escmid.org/escmid_publications/eccmid_abstract_book
   Google Scholar
• Prattes J, Zurl C, Azie N, et al. Clinical Experience of Oral Ibrexafungerp for Treatment of Four Patients with Invasive Candidiasis from the FURI Study. In ECCMID 2020 Abstract Book. Abstract #988, page 524. Available at: https://www.escmid.org/escmid_publications/eccmid_abstract_book
   Google Scholar